A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
SCARCE is a non-comparative randomized, 2:1 phase II study. The purpose of this study is to
assess the progression-free survival rate at 12 months. (evaluation according with RECISTv1.1
criteria).
For all patients, CT scan will be planned at baseline, and every 8 weeks until 12 months from
randomization (or disease progression), and every 12 weeks thereafter.
PET scan will be performed at baseline, at the end of mDCF treatment, and at 12 months after
randomization (in absence of disease progression).
CT scan and PET scan will be collected for a centralized review.
Phase:
Phase 2
Details
Lead Sponsor:
GERCOR - Multidisciplinary Oncology Cooperative Group